Cambridge, England And Waltham, Mass, May 1, 2023 /PRNewswire/ — Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCMA global leader in the supply of life science research instruments, note the Form 13D filed today by founder and former director Dr. Jonathan Milner and related press reports.
The company communicates regularly with Dr. Milner, including recently Friday April 282023.
The Company values Dr. Milner’s contributions and input and looks forward to actively engaging with him and all of our shareholders. The board of directors and management team remain committed to creating value for all shareholders and will continue to take steps to achieve that objective.
About Abcam plc
As an innovator in reagents and tools, Abcam’s mission is to serve life science researchers worldwide to accelerate their mission. Providing tools and scientific support to the research and clinical communities, the company provides highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
A pioneer in data sharing and e-commerce in the life sciences, Abcam’s ambition is to be the most influential company in the life sciences by helping to develop global understanding of biology and disease pathogenesis, which in turn, leads to new treatments and improved health.
Abcam’s global customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the company continuously expands its portfolio to meet their needs. Transparent customer reviews and data sheets combined with industry-leading validation initiatives give researchers confidence in their results.
In the year Founded in 1998 and headquartered in Cambridge, UK, the company serves clients in over 130 countries. Abcam’s American Depositary Shares (ADS) are traded on the Nasdaq International Options Exchange (NASDAQ: ABCM).
For more information, please visit www.abcam.com Or www.abcamplc.com
This advertisement was published in Contains forward-looking statements within the meaning of the Private Securities Litigation Amendment Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “could,” “could,” “could,” “may,” “should,” “expect,” “plan,” “anticipate,” “anticipate,” “expect,” “believe,” “estimate,” “anticipate,” “potential,” “continue,” “consider,” “possible” or the negatives of such words or other synonyms, although not all forward-looking statements contain such words. They are not historical facts, nor are they guarantees of future performance. Any express or implied statements that are not historical facts contained in this announcement should be considered forward-looking statements, including without limitation Abcam’s portfolio and aspirations and our future results of operations and financial position. 2023 Outlook and 2024 performance goals are not guarantees, but involve known and unknown risks and uncertainties that may cause results to differ materially from projected results, including, without limitation: challenges in implementing our strategies for revenue growth; competitive challenges; development of new products or existing products; the need to improve, and adapt to, technological changes or to respond to the introduction of new products by competitors to remain competitive; to discontinue or reduce our customers’ expenditures on research, development, production or other scientific endeavors; the inability to successfully identify or integrate acquired businesses or assets, or the businesses we acquire; or inability to fully realize the expected benefits of assets; The ongoing COVID-19 pandemic continues to impact our business, including variables, and the impact it will have on our operations and supply chains. the inability to successfully use, access and maintain information systems and implement new systems to meet our changing needs; cybersecurity risks and failure to maintain the confidentiality, integrity and availability of our computer hardware, software and Internet applications and related devices and functions; inability to successfully manage our current and future growth; significant interruptions in our operations; Our products fail to meet applicable quality standards, specifications and performance standards; failure to protect and improve our brand and reputation; ability to respond to adverse geopolitical or economic changes affecting life science funding; Failure to deliver on transformational development projects; our dependence on management and highly skilled personnel and our ability to attract and retain these highly skilled personnel; and as a foreign private issuer, we are exempt from many regulations under U.S. securities laws and Nasdaq’s corporate governance rules and are permitted to file less information with the SEC than U.S. companies, which may limit the information available to holders of our U.S. depositary shares (“ADSs”); and other important factors are discussed under the heading “Risk Factors” in Abcam’s Annual Report on Form 20-F for the year ended December 31, 2022 (“Annual Report”) filed with the US Securities and Exchange Commission (“SEC”). March 20, 2023Available on the SEC website www.sec.gov, as such factors may be updated from time to time in Abcam’s subsequent filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abikam disclaims any obligation or duty to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
Use of non-IFRS financial measures
To supplement our audited financial results prepared in accordance with International Financial Reporting Standards (IFRS), we present adjusted operating profit, adjusted profit margin, and total constant currency revenue (“CER revenue”), which are unstructured financial measures. with IFRS (“Non-IFRS Financial Measures”). We believe that the presentation of these non-IFRS financial measures provides valuable information about our operating results and enhances the overall understanding of our past and future financial performance, allowing for greater transparency by management on key financial and operational measures. Decision making. These non-IFRS financial measures are additional in nature and should not be considered separately, or as a substitute for, financial measures prepared in accordance with IFRS, as they include some that are not included and/or are not included and/or are included in the more direct IFRS financial measures. In addition, other companies calculate these non-IFRS financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
Management provides important information to investors and others such as (a) adjusted operating profit, adjusted operating profit margin, management regularly evaluates these measures as important indicators of our operating performance and makes decisions based on them, (b) CER revenue provides important information to investors and others Management periodically This measure is used to identify business performance from period to year and to make decisions based on it, and (c) adjusted sales, general and administrative expenses and are adjusted. Research and development expenses provide valuable information to investors and others, management evaluates these measures periodically or year-over-year to determine the performance of the business and make decisions based on this, and (d) provides useful free cash flow. Information for investors and others because the management regularly evaluates this measure as an important indicator of how much cash is available excluding capital-related items and shows the amount of money available for investment or financing needs after removing capital-related items, and makes decisions based on it.
Please see “Non-IFRS Financial Measures” below for a qualitative reconciliation of non-IFRS financial measures that directly compete with their IFRS financial measures in this transaction amendment. We describe:
- Adjusted operating profit Profit for the period/year before accounting for finance income, finance costs, taxes, special items, share-based payments and acquisition intangibles. Special items include certain cash and non-cash items that we believe do not reflect our normal business operations. And we determine that items are unique by distinguishing them by their characteristics and their chance or importance (“Special Items”). As a result, the composition of special items may vary from season to year.
- Adjusted operating profit margin Adjusted operating profit as a percentage of revenue.
- CR Our overall revenue growth from one fiscal year/year to the next is growing at constant exchange rates.
Management has not been able to provide adjusted net profit, adjusted net profit margin and CER revenue with their respective direct equivalents of IFRS financials operating profit, operating profit and reported revenue on a forward-looking basis. These IFRS financial measures are not within our control and/or cannot be reasonably predicted. Such information could have a material and unpredictable effect on our future financial results.
Vice President, Investor Relations
152 Grove Street, Building 1100
Waltham, MA 02453
E: [email protected]
Source Abcam PLC
We offer you some site tools and assistance to get the best result in daily life by taking advantage of simple experiences